Physician profile
Mary Burden
NPI 1598725780
$1,066.87
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $162 · 2021: $38.43 · 2022: $346 · 2023: $134 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $267.83 | 2019-2022 | |
| Amgen INC. | $119.35 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $112.12 | 2019-2024 | Rexulti |
| Vifor Pharma, INC. | $108.99 | 2019-2023 | Veltassa |
| Genentech USA, INC. | $106.11 | 2023 | Ocrevus |
| Mallinckrodt Hospital Products INC. | $85.44 | 2022 | |
| Opko Pharmaceuticals, LLC | $57.21 | 2019-2020 | |
| Corium, LLC | $52.13 | 2024 | Azstarys |
| Fresenius USA Marketing, INC. | $40.75 | 2019-2022 | |
| Smith+Nephew, INC. | $24.22 | 2019 | |
| Lundbeck LLC | $19.77 | 2024 | Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $15.15 | 2024 | Invega Sustenna |
| Akebia Therapeutics INC | $14.41 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.44 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.